202 related articles for article (PubMed ID: 22113481)
1. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi.
Helmbold P; Richter AM; Walesch S; Skorokhod A; Marsch WCh; Enk A; Dammann RH
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):687-94. PubMed ID: 22113481
[TBL] [Abstract][Full Text] [Related]
2. Frequent epigenetic inactivation of RASSF10 in thyroid cancer.
Schagdarsurengin U; Richter AM; Wöhler C; Dammann RH
Epigenetics; 2009 Nov; 4(8):571-6. PubMed ID: 19934646
[TBL] [Abstract][Full Text] [Related]
3. Claudin11 Promoter Hypermethylation Is Frequent in Malignant Melanoma of the Skin, but Uncommon in Nevus Cell Nevi.
Walesch SK; Richter AM; Helmbold P; Dammann RH
Cancers (Basel); 2015 Jul; 7(3):1233-43. PubMed ID: 26198249
[TBL] [Abstract][Full Text] [Related]
4. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer.
Wei Z; Chen X; Chen J; Wang W; Xu X; Cai Q
Biochem Biophys Res Commun; 2013 Mar; 432(4):632-7. PubMed ID: 23428420
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma.
Dansranjavin T; Wagenlehner F; Gattenloehner S; Steger K; Weidner W; Dammann R; Schagdarsurengin U
Prostate; 2012 Oct; 72(14):1550-8. PubMed ID: 22415519
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
7. RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer.
Li Z; Chang X; Dai D; Deng P; Sun Q
Oncol Rep; 2014 Apr; 31(4):1661-8. PubMed ID: 24573726
[TBL] [Abstract][Full Text] [Related]
8. RASSF10 is epigenetically inactivated and induces apoptosis in lung cancer cell lines.
Wang Y; Ma T; Bi J; Song B; Zhou Y; Zhang C; Gao M
Biomed Pharmacother; 2014 Apr; 68(3):321-6. PubMed ID: 24433832
[TBL] [Abstract][Full Text] [Related]
9. Promoter CpG island hypermethylation in dysplastic nevus and melanoma: CLDN11 as an epigenetic biomarker for malignancy.
Gao L; van den Hurk K; Moerkerk PTM; Goeman JJ; Beck S; Gruis NA; van den Oord JJ; Winnepenninckx VJ; van Engeland M; van Doorn R
J Invest Dermatol; 2014 Dec; 134(12):2957-2966. PubMed ID: 24999589
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic inactivation of the RAS-effector gene RASSF2 in lung cancers.
Kaira K; Sunaga N; Tomizawa Y; Yanagitani N; Ishizuka T; Saito R; Nakajima T; Mori M
Int J Oncol; 2007 Jul; 31(1):169-73. PubMed ID: 17549418
[TBL] [Abstract][Full Text] [Related]
11. Decreased expression and frequent promoter hypermethylation of RASSF2 and RASSF6 correlate with malignant progression and poor prognosis of gastric cardia adenocarcinoma.
Guo W; Dong Z; Guo Y; Shen S; Guo X; Kuang G; Yang Z
Mol Carcinog; 2016 Nov; 55(11):1655-1666. PubMed ID: 26456015
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation profiling of distant breast cancer metastases.
Schrijver WA; Jiwa LS; van Diest PJ; Moelans CB
Breast Cancer Res Treat; 2015 May; 151(1):41-55. PubMed ID: 25841351
[TBL] [Abstract][Full Text] [Related]
13. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice.
Richter AM; Woods ML; Küster MM; Walesch SK; Braun T; Boettger T; Dammann RH
Oncogene; 2020 Apr; 39(15):3114-3127. PubMed ID: 32047266
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
15. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway.
Li X; Liang Q; Liu W; Zhang N; Xu L; Zhang X; Zhang J; Sung JJ; Yu J
Oncogene; 2016 May; 35(19):2453-64. PubMed ID: 26279301
[TBL] [Abstract][Full Text] [Related]
16. DNA hypermethylation of tumor suppressor genes RASSF6 and RASSF10 as independent prognostic factors in adult acute lymphoblastic leukemia.
Younesian S; Shahkarami S; Ghaffari P; Alizadeh S; Mehrasa R; Ghavamzadeh A; Ghaffari SH
Leuk Res; 2017 Oct; 61():33-38. PubMed ID: 28869817
[TBL] [Abstract][Full Text] [Related]
17. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias.
Hesson LB; Dunwell TL; Cooper WN; Catchpoole D; Brini AT; Chiaramonte R; Griffiths M; Chalmers AD; Maher ER; Latif F
Mol Cancer; 2009 Jul; 8():42. PubMed ID: 19570220
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
19. RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells.
Mezzanotte JJ; Hill V; Schmidt ML; Shinawi T; Tommasi S; Krex D; Schackert G; Pfeifer GP; Latif F; Clark GJ
Epigenetics; 2014 Nov; 9(11):1496-503. PubMed ID: 25482183
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis.
Hill VK; Underhill-Day N; Krex D; Robel K; Sangan CB; Summersgill HR; Morris M; Gentle D; Chalmers AD; Maher ER; Latif F
Oncogene; 2011 Feb; 30(8):978-89. PubMed ID: 20956940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]